首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1566197

生物製药市场规模、份额、成长分析，按类型、按应用、按分销管道、按地区 - 行业预测，2024-2031

Biopharmaceuticals Market Size, Share, Growth Analysis, By Type (Vaccines, Enzymes), By Application (Cardiology, Oncology), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球生物製药市场规模将为2630.2亿美元，从2023年的2864亿美元增长到2031年的5660.8亿美元，在预测期内（2024-2031年）预计复合年增长率为8.89%。

生物製药公司向其他生物製药公司提供包装和药品製造等合约服务。这将使大型生物製药公司重新考虑其生产活动，并专注于药物发现和行销。许多没有内部生产能力的中小型生技公司将灌装和成品生产外包，以减少资本支出。生物製药是利用生物技术製造的医疗药物，涉及从生物来源中提取蛋白质和核酸。大多数生物药品生物来源。基因改造生物是经过基因改造并用于生产生物製药的动物或植物，儘管这种方法仍然存在争议并且目前正在测试中。重组人胰岛素是首批核准的治疗物质之一，目前市面上有近300种生物药。该行业的成长受到几个关键因素的推动，包括人口老化、意识增强和医疗保健成本上升。此外，生物製药新产品的核准和研发进展预计将进一步利好市场。然而，该行业面临的主要挑战之一是这些药品的成本高昂，需要大幅降低成本以确保业务永续性。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Pfizer Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Bayer AG
Eli Lilly and Company
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
GSK plc
Takeda Pharmaceutical Company Limited
Amgen Inc.
Biogen Idec
Regeneron Pharmaceuticals, Inc.
Vertex Pharmaceuticals Inc.
Astellas Pharma Inc.
Chugai Pharmaceutical Co., Ltd.
UCB SA
Incyte Corporation

简介目录

Product Code: SQMIG35H2058

Global Biopharmaceuticals Market size was valued at USD 263.02 billion in 2022 and is poised to grow from USD 286.40 billion in 2023 to USD 566.08 billion by 2031, growing at a CAGR of 8.89% during the forecast period (2024-2031).

A biopharmaceutical company provides contract services to other biopharmaceutical firms, including packaging and drug manufacturing. This allows larger biopharmaceutical organizations to reevaluate their production activities, enabling them to focus on drug discovery and marketing. Many smaller biotechnology companies, lacking in-house production capacity, outsource fill and finish manufacturing to lower capital expenditures. Biopharmaceuticals are medical drugs produced using biotechnology, extracting proteins and nucleic acids from biological sources. Most biopharmaceuticals are derived from living organisms. The term ""transgenic organisms"" refers to genetically modified plants and animals, which are used in biopharmaceutical production, though this method remains contentious and is still undergoing trials. Recombinant human insulin was among the first approved therapeutic substances, and currently, nearly 300 biopharmaceutical products are available on the market. The growth of this sector is driven by several key factors, including an aging population, increased awareness, and rising healthcare costs. Additionally, ongoing research and development, along with the approval of new biopharmaceutical products, is expected to further benefit the market. However, one of the industry's major challenges is the high cost of these drugs, which needs to be significantly reduced to ensure business sustainability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Market Segmental Analysis

Global Biopharmaceuticals Market is segmented by Type, Application, Distribution Channel, and Region. Based on Type, the market is segmented into Immunomodulators (Monoclonal Antibodies, Cytokines, Interferons, Others), Enzymes (Hydrolases, Lyases, Oxidoreductases, Others), Vaccines (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated, Toxoid), Hormones (Human Growth Hormones, Insulin, Thyroid Stimulating Hormones, Others), Others . Based on Application, the market is segmented into Cardiology, Oncology, Respiratory, Immunology, Neurology, Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Drivers of the Global Biopharmaceuticals Market

Chronic diseases such as cancer, diabetes, and heart disease are the leading causes of death and disability globally. Biopharmaceuticals based on proteins offer effective treatments for various cancers. Key contributors to this health crisis include increased tobacco use, smoking, exposure to secondhand smoke, poor dietary habits, excessive alcohol consumption, and a sedentary lifestyle. According to the American Heart Association, cardiovascular disease (CVD) claims a life every second in the United States. Innovative biotech companies like Invizius and 3P Biopharmaceuticals have developed groundbreaking technologies for cardiovascular disease patients undergoing hemodialysis. The biopharmaceuticals market is projected to grow between 2024 and 2031 due to the rising prevalence of chronic diseases worldwide.

Restraints in the Global Biopharmaceuticals Market

Due to low incomes and the high costs of healthcare, individuals in developing nations struggle to afford biomedicines and therapies, which may hinder significant market growth during the forecast period. According to the United Nations Development Programme, as of 2023, 1.1 billion of 6.1 billion people are poor and live in poverty, limiting their access to improved healthcare facilities. The World Health Organization (WHO) reports that half of the world's population lacks access to essential medical services due to inadequate healthcare infrastructure. These challenges are adversely affecting the biopharmaceuticals market.

Market Trends of the Global Biopharmaceuticals Market

The rapid growth of the biopharmaceuticals market is largely driven by the effective use of monoclonal antibodies and their derivatives in treating conditions like cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases. The COVID-19 pandemic has intensified the demand for specific monoclonal antibodies, with researchers worldwide seeking solutions to the escalating healthcare burden. Notably, the Drug Controller General of India approved Biocon Ltd.'s anti-CD6 IgG1 monoclonal antibody in July 2020 for treating cytokine release syndrome in COVID-19 patients. Additionally, FDA approvals and new product launches, such as MacroGenics' MARGENZATM and GlaxoSmithKline's BLENREP, are expected to further propel market expansion in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Types
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Patent Analysis
Pipeline Analysis
Technology Analysis
Regulatory Landscape
Case Study Analysis
Macro-Economic Factors
PESTEL Analysis
Market Attractiveness Index, 2023

Biopharmaceuticals Market, By Type

Market Overview
Immunomodulators
- Monoclonal Antibodies
- Cytokines
- Interferons
- Others
Enzymes
- Hyrdolases
- Lyases
- Oxidoreductases
- Others
Vaccines
- Recombinant/Conjugate/Subunit
- Inactivated
- Live Attenuated
- Toxoid
Hormones
- Human Growth Hormones
- Insulin
- Thyroid Stimulating Hormones
- Others
Others

Biopharmaceuticals Market, By Application

Market Overview
Cardiology
Oncology
Respiratory
Immunology
Neurology
Others

Biopharmaceuticals Market, By Distribution Channel

Market Overview
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

Biopharmaceuticals Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Idec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chugai Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments